Search Results - "Koerber, S. A."

Fibroblast activation protein inhibitor (FAPI) PET for diagnostics and advanced targeted radiotherapy in head and neck cancers by Syed, M., Flechsig, P., Liermann, J., Windisch, P., Staudinger, F., Akbaba, S., Koerber, S. A., Freudlsperger, C., Plinkert, P. K., Debus, J., Giesel, F., Haberkorn, U., Adeberg, S.

“…Purpose Cancer-associated fibroblasts (CAFs) expressing fibroblast activation protein (FAP) have been associated with the aggressive nature of head and neck…”
Get full text

FAP imaging in rare cancer entities—first clinical experience in a broad spectrum of malignancies by Dendl, K., Finck, R., Giesel, F. L., Kratochwil, C., Lindner, T., Mier, W., Cardinale, J., Kesch, C., Röhrich, M., Rathke, H., Gampp, H., Ristau, J., Adeberg, S., Jäger, D., Debus, J., Haberkorn, U., Koerber, S. A.

“…Purpose 68  Ga-FAPI (fibroblast activation protein inhibitor) is a rapidly evolving and highly promising radiotracer for PET/CT imaging, presenting excellent…”
Get full text

Whole-pelvic irradiation with boost to involved nodes and prostate in node-positive prostate cancer—long-term data from the prospective PLATIN-2 trial by Fink, C. A., Wegener, D., Sauer, L. D., Jäkel, C., Zips, D., Debus, J., Herfarth, K., Koerber, S. A.

“…Purpose Node-positive prostate cancer is a potentially curable disease. Definitive radiotherapy to the prostate and lymphatic drainage is an effective…”
Get full text

Stereotactic MRI-guided radiation therapy for localized prostate cancer (SMILE): a prospective, multicentric phase-II-trial by Ristau, J, Hörner-Rieber, J, Buchele, C, Klüter, S, Jäkel, C, Baumann, L, Andratschke, N, Garcia Schüler, H, Guckenberger, M, Li, M, Niyazi, M, Belka, C, Herfarth, K, Debus, J, Koerber, S A

“…Normofractionated radiation regimes for definitive prostate cancer treatment usually extend over 7-8 weeks. Recently, moderate hypofractionation with doses per…”
Get full text

Simultaneous integrated boost concepts in definitive radiation therapy for esophageal cancer: outcomes and toxicity by Ristau, J, Thiel, M, Katayama, S, Schlampp, I, Lang, K, Häfner, M F, Herfarth, K, Debus, J, Koerber, S A

“…Radiation therapy and chemoradiation therapy play a major role in the definitive management of esophageal cancer. Survival in esophageal cancer patients is…”
Get full text

Intrafractional dose variation and beam configuration in carbon ion radiotherapy for esophageal cancer by Haefner, M F, Sterzing, F, Krug, D, Koerber, S A, Jaekel, O, Debus, J, Haertig, M M

“…In carbon ion radiotherapy (CIR) for esophageal cancer, organ and target motion is a major challenge for treatment planning due to potential range deviations…”
Get full text

Impact of Primary Staging with Fibroblast Activation Protein Specific Enzyme Inhibitor (FAPI)-PET/CT on Radio-Oncologic Treatment Planning of Patients with Esophageal Cancer by Ristau, J., Giesel, F. L., Haefner, M. F., Staudinger, F., Lindner, T., Merkel, A., Schlittenhardt, J., Kratochwil, C., Choyke, P. L., Herfarth, K., Debus, J., Haberkorn, U., Koerber, S. A.

“…Purpose Quinoline-based ligands targeting cancer-associated fibroblasts have emerged as promising radiopharmaceuticals in different tumor entities. The aim of…”
Get full text

Head-to-head Intra-individual Comparison of [68Ga]-FAPI and [18F]-FDG PET/CT in Patients with Bladder Cancer by Novruzov, E., Dendl, K., Ndlovu, H., Choyke, P. L., Dabir, M., Beu, M., Novruzov, F., Mehdi, E., Guliyev, F., Koerber, S. A., Lawal, I., Niegisch, G., Debus, J., Haberkorn, U., Sathekge, M., Giesel, F. L.

“…Aim/Purpose Fibroblast activation protein-(FAP)-ligands, a novel class of tracers for PET/CT imaging, demonstrated promising results in previous studies in…”
Get full text

Distinguishing Benign and Malignant Findings on [68 Ga]-FAPI PET/CT Based on Quantitative SUV Measurements by Dabir, M., Novruzov, E., Mattes-György, K., Beu, M., Dendl, K., Antke, C., Koerber, S. A., Röhrich, M., Kratochwil, C., Debus, J., Haberkorn, U., Giesel, F. L.

“…Aim/Purpose Fibroblast activation protein (FAP) is overexpressed by cancer-associated fibroblasts. However, activated fibroblasts have been shown to play a…”
Get full text

Detecting and Locating the Site of Local Relapse Using 18F-PSMA-1007 Imaging After Primary Treatment of 135 Prostate Cancer Patients—Potential Impact on PSMA-Guided Radiation Therapy by Koerber, S. A., Kroener, R. C., Dendl, K., Kratochwil, C., Fink, C. A., Ristau, J., Winter, E., Herfarth, K., Hatiboglu, G., Hohenfellner, M., Haberkorn, U., Debus, J., Giesel, F. L.

“…Purpose Due to limited imaging options, the visualization of a local relapse of prostate cancer used to pose a considerable challenge. However, since the…”
Get full text

The risk of second malignancies following prostate cancer radiotherapy in the era of conformal radiotherapy: a statement of the Prostate Cancer Working Group of the German Society of Radiation Oncology (DEGRO) by Zamboglou, C, Aebersold, D M, Albrecht, C, Boehmer, D, Ganswindt, U, Schmidt-Hegemann, N-S, Hoecht, S, Hölscher, T, Koerber, S A, Mueller, A-C, Niehoff, P, Peeken, J C, Pinkawa, M, Polat, B, Spohn, S K B, Wolf, F, Zips, D, Wiegel, T

“…A significant number of prostate cancer patients are long-term survivors after primary definitive therapy, and the occurrence of late side effects, such as…”
Get full text

Prostate cancer and elective nodal radiation therapy for cN0 and pN0—a never ending story? by Koerber, S. A, Höcht, S, Aebersold, D, Albrecht, C, Boehmer, D, Ganswindt, U, Schmidt-Hegemann, N.-S, Hölscher, T, Mueller, A.-C, Niehoff, P, Peeken, J. C, Pinkawa, M, Polat, B, Spohn, S. K. B, Wolf, F, Zamboglou, C, Zips, D, Wiegel, T

“…For prostate cancer, the role of elective nodal irradiation (ENI) for cN0 or pN0 patients has been under discussion for years. Considering the recent…”
Get full text

Prostate cancer and elective nodal radiation therapy for cN0 and pN0—a never ending story?: Recommendations from the prostate cancer expert panel of the German Society of Radiation Oncology (DEGRO) by Koerber, S. A., Höcht, S., Aebersold, D., Albrecht, C., Boehmer, D., Ganswindt, U., Schmidt-Hegemann, N.-S., Hölscher, T., Mueller, A.-C., Niehoff, P., Peeken, J. C., Pinkawa, M., Polat, B., Spohn, S. K. B., Wolf, F., Zamboglou, C., Zips, D., Wiegel, T.

“…For prostate cancer, the role of elective nodal irradiation (ENI) for cN0 or pN0 patients has been under discussion for years. Considering the recent…”
Get full text

Post-prostatectomy radiotherapy adversely affects urinary continence irrespective of radiotherapy regime by Nyarangi-Dix, J. N., Steimer, J., Bruckner, T., Jakobi, H., Koerber, S. A., Hadaschik, B., Debus, J., Hohenfellner, M.

“…Purpose To investigate the influence of different postoperative radiotherapy (RT) regimes on post-prostatectomy continence and QoL. Methods Men after…”
Get full text

Intensity-modulated proton therapy, volumetric-modulated arc therapy, and 3D conformal radiotherapy in anaplastic astrocytoma and glioblastoma: A dosimetric comparison by Adeberg, S., Harrabi, S. B., Bougatf, N., Bernhardt, D., Rieber, J., Koerber, S. A., Syed, M., Sprave, T., Mohr, A., Abdollahi, A., Haberer, T., Combs, S. E., Herfarth, K., Debus, J., Rieken, S.

“…Purpose The prognosis for high-grade glioma (HGG) patients is poor; thus, treatment-related side effects need to be minimized to conserve quality of life and…”
Get full text

Stereotactic ultrahypofractionated MR-guided radiotherapy for localized prostate cancer – Acute toxicity and patient-reported outcomes in the prospective, multicenter SMILE phase II trial by Fink, C.A., Ristau, J., Buchele, C., Klüter, S., Liermann, J., Hoegen-Saßmannshausen, P., Sandrini, E., Lentz-Hommertgen, A., Baumann, L., Andratschke, N., Baumgartl, M., Li, M., Reiner, M., Corradini, S., Hörner-Rieber, J., Bonekamp, D., Schlemmer, H.-P., Belka, C., Guckenberger, M., Debus, J., Koerber, S.A.

“…•Daily adaptive MR-guided ultrahypofractionated radiotherapy for prostate cancer is feasible with low genitourinary and gastrointestinal toxicity.•Daily…”
Get full text

Imaging of oligometastatic disease in selected urologic cancers by Koerber, S A, Fink, C A, Dendl, K, Schmitt, D, Niegisch, G, Mamlins, E, Giesel, F L

“…Local treatment of the primary or metastatic sites in urologic malignancies is promising when compared to systemic therapy alone, leading to the definition of…”
Get full text

Impact of 68Ga-FAPI PET/CT Imaging on the Therapeutic Management of Primary and Recurrent Pancreatic Ductal Adenocarcinomas by Röhrich, Manuel, Naumann, Patrick, Giesel, Frederik L, Choyke, Peter L, Staudinger, Fabian, Wefers, Annika, Liew, Dawn P, Kratochwil, Clemens, Rathke, Hendrik, Liermann, Jakob, Herfarth, Klaus, Jäger, Dirk, Debus, Jürgen, Haberkorn, Uwe, Lang, Matthias, Koerber, Stefan A

“…Pancreatic ductal carcinoma (PDAC) is a highly lethal cancer, and early detection and accurate staging are critical to prolonging survival. PDAC typically has…”
Get full text

Bildgebung oligometastasierter Tumoren des Harntraktes by Koerber, S. A., Fink, C. A., Dendl, K., Schmitt, D., Niegisch, G., Mamlins, E., Giesel, F. L.

“…Zusammenfassung Hintergrund Klinische Studien zeigen für die Lokaltherapie von Primarius und Metastasen urologischer Tumoren im metastasierten Stadium Vorteile…”
Get full text

MR-guided adaptive versus ITV-based stereotactic body radiotherapy for hepatic metastases (MAESTRO): a randomized controlled phase II trial by Hoegen, P, Zhang, K S, Tonndorf-Martini, E, Weykamp, F, Regnery, S, Naumann, P, Lang, K, Ristau, J, Körber, S A, Dreher, C, Buchele, C, Rippke, C, Renkamp, C K, Paul, K M, König, L, Büsch, C, Krisam, J, Sedlaczek, O, Schlemmer, H-P, Niyazi, M, Corradini, S, Debus, J, Klüter, S, Hörner-Rieber, J

“…Stereotactic body radiotherapy (SBRT) is an established local treatment method for patients with hepatic oligometastasis or oligoprogression. Liver metastases…”
Get full text